The Editorial discusses the sudden anxiety caused by the publication in the New England Journal of Medicine (NEJM) of a systematic review of trials using rosiglitazone. The NEJM analysis suggests that the risk of a heart attack increases by 43% for patients taking rosiglitazone compared to control groups, and the risk of death by heart attack by 64%.
The tone of the NEJM paper is one of urgency, yet GSK has responded by stating it “strongly disagrees” with its conclusions. Who is right?
Of studies to date, the two most reliable to inform decision making are DREAM (published in The Lancet) and ADOPT (published in the NEJM). DREAM, which involved over 5,000 patients, recorded small increases in cardiovascular events compared to controls, which were not statistically significant. ADOPT involved more than 4,000 patients, with the only significant relevant finding an excess of congestive heart failure episodes for rosiglitazone-treated patients compared with glyburide (22 vs 9 events).
When taken together, the Editorial concludes these results could certainly be a matter of concern; but it says that patients, physicians and the US Food and Drug Administration can reasonably await the results of RECORD – a phase III trial specifically designed to analyse cardiovascular events connected to use of rosiglitazone.
The Editorial says: “Until the results of RECORD are in, it would be premature to overinterpret a meta-analysis that the authors and NEJM editorialists all acknowledge contains important weaknesses.”
It concludes: “To avoid unnecessary panic among patients, a calmer and more considered approach to the safety of rosiglitazone is needed.”
Tony Kirby | alfa
Spanish scientists create a 3-D bioprinter to print human skin
24.01.2017 | Carlos III University of Madrid
Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital
A Swedish-German team of researchers has cleared up a key process for the artificial production of silk. With the help of the intense X-rays from DESY's...
For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.
According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
24.01.2017 | Physics and Astronomy
24.01.2017 | Life Sciences
24.01.2017 | Health and Medicine